SEARCH

Current Edition

Deciphera

Facing challenges, Deciphera cuts workforce by a third

Deciphera is regrouping after Qinlock failed to outperform standard of care in a Phase 3 study testing the drug as a second-line treatment for GIST. …

Continue Reading →